Acute LeukemiaThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you your search results in order of date.

Pages: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30

7165 records returned

Depressive disease in children with acute lymphocytic leukemia and end stage of renal disease: case series studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: The frequency of MED was not different from the literature, but the frequency of DD was higher. In opposition to what was expected, there wasn't difference between the ages in MED. However, in agreement with the literature, it prevailed the highest ages in DD. (Source: Jornal Brasileiro de Psiquiatria)
Source: Jornal Brasileiro de Psiquiatria - November 20, 2009 Category: Psychiatry Source Type: journals

Vincristine-Induced Unilateral Ptosis in a ChildEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vincristine is a vinca alkaloid used in combination with other agents in the treatment of solid tumors, lymphoma, and leukemia, as well as for idiopathic thrombocytopenic purpura and autoimmune hemolytic anemia. A dose-limiting complication of vinca alkaloids is neurotoxicity. Vincristine is the oldest and also the most neurotoxic agent in this group. Described here is the case of a 4-year-old girl with unilateral palpebral ptosis. She has been diagnosed with precursor B-cell acute lymphoblastic leukemia. Ptosis was noted on the 45th day of therapy, and the last vincristine was administered on the 28th day of protocol 1. V...
Source: Pediatric Neurology - November 20, 2009 Category: Neurology Authors: Orhan Gursel, Erkan Sari, Demet Altun, A. Avni Atay, Ridvan Akin Tags: Case Reports Source Type: journals

Diagnosis of biphenotypic acute leukemia: a paradigmatic approach.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Biphenotypic acute leukemia (BAL), or acute leukemia with a single population of blasts coexpressing markers of two different lineages, is a rare clinical entity. To define BAL, a scoring system was proposed by the European Group of Immunological Markers for Leukemias (EGIL) in 1995. However, increasing evidence suggests that this system has limitations, as acknowledged by the 2008 World Health Organization (WHO) Classification of Tumors of Hematopoietic and Lymphoid Tissues. Although substantially improved in relation to the EGIL, the new WHO Classification is still not optimal for guiding the clinical management of p...
Source: International Journal of Clinical and Experimental Pathology - November 19, 2009 Category: Pathology Authors: Zhao XF, Gojo I, York T, Ning Y, Baer MR Tags: Int J Clin Exp Pathol Source Type: journals

AML1 amplification and 17q25 deletion in a case of childhood acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report a case of childhood acute lymphoblastic leukemia (ALL) with both acute myeloid leukemia 1 (AML1) amplification and 17q25 deletion. AML1 gene is located on 21q22 and encodes a transcription factor. AML1 amplification is a common finding in childhood ALL, and itis observed as an increase in gene copy number by the FISH analysis. The mechanism of AML1 amplification is not associated with AML1 gene mutations. The 17q25 is a gene-rich chromosomal location and distinct abnormalities of this region have been observed in previous cases of different kinds of leukemia. Deletion of the 17q25 region has been reported in two ...
Source: Journal of Clinical Laboratory Analysis - November 19, 2009 Category: Laboratory Medicine Authors: Tuna Gulten, Tahsin Yakut, Mutlu Karkucak, Birol Baytan, Adalet Meral Gune[scedil] Tags: Original Articles Source Type: journals

Age-Specific Differences in Oncogenic Pathway Dysregulation and Anthracycline Sensitivity in Patients With Acute Myeloid Leukemia [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion AML in the elderly represents a distinct biologic entity characterized by unique patterns of deregulated signaling pathway variations that contributes to poor survival and anthracycline resistance. These insights should enable development and adjustments of clinically meaningful treatment strategies in the older patient population. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 18, 2009 Category: Cancer & Oncology Authors: Rao, Valk, Metzeler, Acharya, Tuchman, Stevenson, Rizzieri, Delwel, Buske, Bohlander, Potti, Lowenberg Tags: Epidemiology, Translational Oncology, Hematologic, Other, Gene Expression and Profiling Hematologic Malignancies Source Type: journals

Chronic myelogenous leukemia and benzene exposure: a systematic review and meta-analysis of the case-control literature.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Benzene exposure is well demonstrated as a cause of acute myelogenous leukemia, but not of chronic myelogenous leukemia. Previous literature reviews based on case series and cohort studies have not shown an association. We have now conducted a literature search for case-control studies that examine the association between benzene exposure and chronic myelogenous leukemia. Six case-control studies have been found. These derive from occupational groups, cancer registries, and a clinical laboratory. Their exposure ascertainments are all based on job histories, job-exposure matricies, or industrial hygiene data. The odds r...
Source: Chemico-Biological Interactions - November 18, 2009 Category: Molecular Biology Authors: Lamm SH, Engel A, Joshi KP, Byrd DM, Chen R Tags: Chem Biol Interact Source Type: journals

Erratum to: Results of FLT3 mutation screening and correlations with immunophenotyping in 169 Brazilian patients with acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory ErratumDOI 10.1007/s00277-009-0860-1Authors Antonio R. Lucena-Araujo, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilDanielle L. Souza, University of São Paulo Hematology Division, Department of Internal Medicine, National Institute of Science and Technology on Cell Based Therapy, Medical School of Ribeirão Preto Ribeirão Preto BrazilFabio Morato de Oliveira, University of São Paulo Hematology Division, Department of Internal...
Source: Annals of Hematology - November 18, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Cytogenetic features and prognosis analysis in Chinese patients with myelodysplastic syndrome: a multicenter studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we retrospectively analyzed clinical and cytogenetic data from 435 Chinese adult primary MDS patients. In addition, we evaluated the prognostic value of the World Health Organization classification as well as six prognostic scoring systems in these patients. The median follow-up time was 25.1 months (5.5–53.2). Of the 435 patients, 186 (42.8%) had died and 40 (9.2%) had progressed to acute myeloid leukemia. Multivariate analysis identified older age, higher percent of marrow blasts, and poor-risk IPSS cytogenetics as characteristics associated with worse survival and higher risk of leukemia transf...
Source: Annals of Hematology - November 18, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Expression of interleukin 15 in primary adult acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Interleukin-15 (IL-15) has been associated with the growth, survival and biological behavior of leukemic cells and response to therapy. We determined the expression of IL-15 in lymphoblasts and evaluated its potential impact on the outcome in adult acute lymphoblastic leukemia (ALL).Between June 1999 and June 2006, ALL samples were collected from 87 adult patients before initiation of antineoplastic therapy. These patients were enrolled in the German Multicenter Acute Lymphoblastic Leukemia June 1999 and July 2003 study trials. The expression of IL-15 in leukemic cells was analyzed by real-time polymerase chain reaction.Th...
Source: Cancer - November 18, 2009 Category: Cancer & Oncology Authors: Shuling Wu, Lars Fischer, Nicola Gökbuget, Stefan Schwartz, Thomas Burmeister, Michael Notter, Dieter Hoelzer, Hendrik Fuchs, Igor Wolfgang Blau, Wolf K Hofmann, Eckhard Thiel Source Type: journals

Infections in acute myeloid leukemia: an analysis of 382 febrile episodes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Gupta A, Singh M, Singh H, Kumar L, Sharma A, Bakhshi S, Raina V, Thulkar S. (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - November 18, 2009 Category: Respiratory Medicine Source Type: consumer

Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Imahashi N, Inamoto Y, Seto A, Watanabe K, Nishiwaki S, Yanagisawa M, Shinba M, Yasuda T, Kuwatsuka Y, Atsuta Y, Kodera Y, Miyamura K. Impact on relapse of corticosteroid therapy after allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Clin Transplant 2009 DOI: 10.1111/j.1399-0012.2009.01158.x© 2009 John Wiley & Sons A/S.Abstract: Corticosteroids are often used following allogeneic hematopoietic stem cell transplantation (HSCT) to control complications such as graft-versus-host disease (GVHD). However, there is some concern that corticosteroids may suppress the graft-versus-leukemia effect and i...
Source: Clinical Transplantation - November 18, 2009 Category: Transplant Surgery Authors: Nobuhiko Imahashi, Yoshihiro Inamoto, Aika Seto, Keisuke Watanabe, Satoshi Nishiwaki, Mayumi Yanagisawa, Makoto Shinba, Takahiko Yasuda, Yachiyo Kuwatsuka, Yoshiko Atsuta, Yoshihisa Kodera, Koichi Miyamura Source Type: journals

Relapse Risk After Umbilical Cord Blood Transplantation: Enhanced Graft-Versus-Leukemia Effect in Recipients of 2 UnitsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
UCB transplant with 2 partially HLA-matched units enhances graft-vs-leukemia effect and lowers the risk of relapse. Umbilical cord blood (UCB) transplantation is potentially curative for acute leukemia.... (Source: OncologySTAT Journal Scans)
Source: OncologySTAT Journal Scans - November 17, 2009 Category: Cancer & Oncology Source Type: journals

Structure of Helicobacter pyloril-asparaginase at 1.4 Å resolutionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bacterial l-asparaginases have been used in the treatment of childhood acute lymphoblastic leukaemia for over 30 years. Their therapeutic effect is based on their ability to catalyze the conversion of l-asparagine, an essential amino acid in certain tumours, to l-aspartic acid and ammonia. Two l-asparaginases, one from Escherichia coli and the other from Erwinia chrysanthemi, have been widely employed in clinical practice as anti-leukaemia drugs. However, l-asparaginases are also able to cause severe side effects owing to their intrinsic glutaminase activity. Helicobacter pylori l-asparaginase (HpA) has been reported to ...
Source: Acta Crystallographica Section D - November 17, 2009 Category: Biochemistry Authors: Dhavala, P.Papageorgiou, A.C. Tags: l-asparaginases active site leukaemia treatment therapeutic enzymes research papers Source Type: journals

Molecular diagnostics in acute leukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Clinical Chemistry and Laboratory Medicine 47 (11): 1333-1341 Abstract Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) both represent highly heterogeneous entities on the basis of diverse cyto- and molecular genetic alterations with considerable influence on prognosis and therapeutic decisions. In recent years, insights into the complex network of molecular markers underlying this diversity have shown marked progress due to the detection of novel mutations, such as nucleophosmin gene (NPM1) in AML, and due to the description of cooperation pathways in leukemogenesis. Also, targeted therapeutic strategie...
Source: Clinical Chemistry and Laboratory Medicine - November 16, 2009 Category: Laboratory Medicine Source Type: journals

Finding May Give Hope To More Leukemia Patients So They May Live Cancer-FreeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 16, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

Finding May Give Hope To More Leukemia Patients So They May Live Cancer-FreeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. Michael Verneris, M.D. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 16, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Two Units Of Umbilical Cord Blood Reduce Risk Of Leukemia RecurrenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 15, 2009 Category: Science Source Type: news

15(S)-Lipoxygenase-1 associates with neutral lipid droplets in macrophage foam cells: evidence of lipid droplet metabolism [Research Articles]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
15(S)-lipoxygenase-1 (15-LO-1) was present in the whole-cell homogenate of an acute human monocytic leukemia cell line (THP-1). Additionally, 15-LO-1 was detected on neutral lipid droplets isolated from THP-1 foam cells. To investigate if 15-LO-1 is active on lipid droplets, we used the mouse leukemic monocytic macrophage cell line (RAW 264.7), which are stably transfected with human 15-LO-1. The RAW 15-LO-1 cells were incubated with acetylated low density lipoprotein to generate foam cells. 15(S)-hydroxyeicosatetraenoic acid [15(S)-HETE], the major 15-LO-1 metabolite of arachidonic acid, was produced in the 15-LO-1 RAW bu...
Source: The Journal of Lipid Research - November 13, 2009 Category: Lipidology Authors: Weibel, G. L., Joshi, M. R., Wei, C., Bates, S. R., Blair, I. A., Rothblat, G. H. Tags: Research Articles Source Type: journals

Voxel-Based Analysis of T2 Hyperintensities in White Matter during Treatment of Childhood Leukemia [PEDIATRICS]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: These analyses identified specific WM tracts involving predominantly the anterior, superior, and posterior corona radiata and superior longitudinal fasciculus, which were at increased risk for the development of T2-weighted hyperintensities during therapy for childhood ALL. These vulnerable regions may be the cause of subsequent cognitive difficulties consistently observed in survivors. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - November 13, 2009 Category: Radiology Authors: Reddick, W.E., Glass, J.O., Johnson, D.P., Laningham, F.H., Pui, C.-H. Tags: PEDIATRICS Source Type: journals

Diagnosis and treatment of maternal acute myeloid leukemia during pregnancy imitating HELLP syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Journal of Perinatal Medicine 37 (6): 713-714 No abstract available (Source: Journal of Perinatal Medicine)
Source: Journal of Perinatal Medicine - November 13, 2009 Category: Perinatology & Neonatology Source Type: journals

U of M researchers find 2 units of umbilical cord blood reduce risk of leukemia recurrenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(University of Minnesota) A new study from the Masonic Cancer Center, University of Minnesota shows that patients who have acute leukemia and are transplanted with two units of umbilical cord blood (UCB) have significantly reduced risk of the disease returning. This finding has the potential to change the current medical practice of using one unit of UCB for treatment of patients who are at high risk for recurrence of leukemia and other cancers of the blood and bone marrow. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - November 13, 2009 Category: Global & Universal Source Type: news

Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Khat activated a distinct cell death pathway in sensitive leukemic cells as compared to camptothecin, involving mitochondrial damage and morphological features of autophagy. This suggests that khat should be further explored in the search for novel experimental therapeutics. (Source: Molecular Cancer)
Source: Molecular Cancer - November 13, 2009 Category: Cancer & Oncology Authors: Therese BredholtElizabeth DimbaHanne HaglandLine WergelandJorn SkavlandKjell FossanKarl TronstadAnne JohannessenOlav VintermyrBjorn Gjertsen Source Type: journals

The role of cytogenetic abnormalities in acute myeloid leukemia with NPM1 mutations and no FLT3 internal tandem duplicationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Blood)
Source: Blood - November 12, 2009 Category: Hematology Authors: Micol, J. B., Boissel, N., Renneville, A., Castaigne, S., Gardin, C., Preudhomme, C., Dombret, H. Tags: CORRESPONDENCE Source Type: journals

Stage-specific Arf tumor suppression in Notch1-induced T-cell acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Frequent hallmarks of T-cell acute lymphoblastic leukemia (T-ALL) include aberrant NOTCH signaling and deletion of the CDKN2A locus, which contains 2 closely linked tumor suppressor genes (INK4A and ARF). When bone marrow cells or thymocytes transduced with a vector encoding the constitutively activated intracellular domain of Notch1 (ICN1) are expanded ex vivo under conditions that support T-cell development, cultured progenitors rapidly induce CD4+/CD8+ T-ALLs after infusion into healthy syngeneic mice. Under these conditions, enforced ICN1 expression also drives formation of T-ALLs in unconditioned CD-1 nude mice, bypas...
Source: Blood - November 12, 2009 Category: Hematology Authors: Volanakis, E. J., Williams, R. T., Sherr, C. J. Tags: Lymphoid Neoplasia Source Type: journals

Gene expression-based classification and regulatory networks of pediatric acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pediatric acute lymphoblastic leukemia (ALL) contains cytogenetically distinct subtypes that respond differently to cytotoxic drugs. Subtype classification can be also achieved through gene expression profiling. However, how to apply such classifiers to a single patient and correctly diagnose the disease subtype in an independent patient group has not been addressed. Furthermore, the underlying regulatory mechanisms responsible for the subtype-specific gene expression patterns are still largely unknown. Here, by combining 3 published microarray datasets on 535 mostly white children's samples and generating a new dataset on...
Source: Blood - November 12, 2009 Category: Hematology Authors: Li, Z., Zhang, W., Wu, M., Zhu, S., Gao, C., Sun, L., Zhang, R., Qiao, N., Xue, H., Hu, Y., Bao, S., Zheng, H., Han, J.-D. J. Tags: Lymphoid Neoplasia Source Type: journals

The BH3-only protein Bim plays a critical role in leukemia cell death triggered by concomitant inhibition of the PI3K/Akt and MEK/ERK1/2 pathwaysEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Mechanisms underlying apoptosis induced by concomitant interruption of the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase 1/2 (MEK/ERK1/2) and phosphatidylinositol 3-kinase (PI3K)/Akt pathways were investigated in human leukemia cells. Inhibition of these pathways using the MEK inhibitor PD184352 or U0126 and the PI3K/Akt inhibitor perifosine strikingly induced apoptosis in multiple malignant human hematopoietic cells, and substantially reduced the colony-forming capacity of primary acute myeloblastic leukemia, but not normal CD34+ cells. These events were associated with pronounced Bim up-re...
Source: Blood - November 12, 2009 Category: Hematology Authors: Rahmani, M., Anderson, A., Habibi, J. R., Crabtree, T. R., Mayo, M., Harada, H., Ferreira-Gonzalez, A., Dent, P., Grant, S. Tags: Myeloid Neoplasia Source Type: journals

Experimental protein for leukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion This study has developed a new method for targeting the NOTCH1 transcription factor. The technique may eventually lead to the development of new drugs for T-ALL and other Notch-related conditions. However, this will be a long-term goal as much more animal and human research will be needed to determine the effectiveness and safety of this new approach. Links To The Headlines Cancer protein 'can be disarmed'. BBC News, November 12 2009 Links To Science Moellering RE, Cornejo M, Davis TN. Direct inhibition of the NOTCH transcription factor complex. Nature 2009; 462: 182-188 (Source: NHS News Feed)
Source: NHS News Feed - November 12, 2009 Category: Consumer Health News Tags: Cancer Source Type: news

Constitutive Activation of the DNA Damage Signaling Pathway in Acute Myeloid Leukemia with Complex Karyotype: Potential Importance for Checkpoint Targeting TherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Genomic instability in solid tumors participates in the oncogenetic process and is associated with the activation of the DNA damage response pathway. Here, we report the activation of the constitutive DNA damage and checkpoint pathway associated with complex karyotypes in samples from patients with acute myeloid leukemia (AML). We show that antagonizing CHK1 kinase with a small inhibitory compound or by RNA interference strongly reduces the clonogenic properties of high–DNA damage level AML samples, particularly those with complex karyotypes. Moreover, we observe a beneficial effect of CHK1 inhibition in high–D...
Source: Cancer Research - November 12, 2009 Category: Cancer & Oncology Authors: Cavelier, C., Didier, C., Prade, N., Mansat-De Mas, V., Manenti, S., Recher, C., Demur, C., Ducommun, B. Tags: Experimental Therapeutics, Molecular Targets, and Chemical Biology Source Type: journals

Modeling interactions between leukemia-specific chromosomal changes, somatic mutations, and gene expression patterns during progression of core-binding factor leukemiasEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In cancer genomes, changes observed during tumor progression can be difficult to separate from nonspecific accumulation of cytogenetic changes due to cancer-associated genetic instability. We studied genetic changes occurring over time in cancers presenting with a relatively simple karyotype, namely two related core-binding factor (CBF) acute myeloid leukemias (AMLs), to assess how specific chromosomal changes are selected based on tumor subtype and acquired somatic mutations. Expression profiles for DNA replication/repair genes and the mutation status of KRAS, NRAS, FLT3, and KIT were compared with the karyotypic changes ...
Source: Genes, Chromosomes and Cancer - November 12, 2009 Category: Cancer & Oncology Authors: Dan Jones, Hui Yao, Angela Romans, Caroline Dando, Sherry Pierce, Gautam Borthakur, Amy Hamilton, Carlos Bueso-Ramos, Farhad Ravandi, Guillermo Garcia-Manero, Hagop Kantarjian Source Type: journals

Polo-like-kinase 1 (PLK1) as a molecular target to overcome SYK-mediated resistance of B-lineage acute lymphoblastic leukaemia cells to oxidative stressEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
This study is the first to identify PLK1 as a regulator of SYK tyrosine kinase and a molecular target to overcome SYK-mediated resistance of B-lineage ALL cells to OS. (Source: British Journal of Haematology)
Source: British Journal of Haematology - November 12, 2009 Category: Hematology Authors: Fatih M. Uckun, Zahide Ozer, Sanjive Qazi, Lisa Tuel-Ahlgren, Chen Mao Source Type: journals

Long-Term Safety of Recombinant Human Growth Hormone in Children.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion: After more than 20 yr, leukemia, a major safety issue initially believed associated with GH, has not been confirmed, but other signals, including risk of second malignancies in patients previously treated with irradiation, have been detected or confirmed through the NCGS. These data further clarify the events associated with rhGH and, although confirming a favorable overall safety profile, they also highlight specific populations at potential risk. PMID: 19906787 [PubMed - as supplied by publisher] (Source: The Journal of Clinical Endocrinology and Metabolism)
Source: The Journal of Clinical Endocrinology and Metabolism - November 11, 2009 Category: Endocrinology Authors: Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B Tags: J Clin Endocrinol Metab Source Type: journals

Gemtuzumab ozogamicin-induced long-term remission in a woman with acute myelomonocytic leukemia and bone marrow relapse following allogeneic transplantation.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A 56-year-old woman with acute myelomonocytic leukemia underwent myeloablative allogeneic hematopoietic stem cell transplantation (allo-SCT) from a matched unrelated donor in her first complete remission (CR). Veno-occlusive disease (VOD) prophylaxis consisted of low-dose heparin and ursodeoxycholic acid. Graft-versus-host disease (GVHD) prophylaxis comprised tacrolimus and short-term methotrexate. On day 14, VOD developed, but gradually resolved with supportive therapy. On day 58, she showed grade II acute GVHD, but this resolved spontaneously. On day 140, she developed hematological relapse with 40.2% marrow infiltra...
Source: International Journal of Hematology - November 11, 2009 Category: Hematology Authors: Sumi M, Ichikawa N, Nasu K, Shimizu I, Ueki T, Ueno M, Kobayashi H Tags: Int J Hematol Source Type: journals

Jumping translocation involving 1q21 during long-term complete remission of acute myeloid leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Content Type Journal ArticleCategory Letter to the EditorDOI 10.1007/s00277-009-0855-yAuthors Sumimasa Nagai, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanYasuhito Nannya, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanTsuyoshi Takahashi, University of Tokyo Department of Hematology and Oncology, Graduate School of Medicine 7-3-1, Hongo, Bunkyo-ku Tokyo 1138655 JapanMineo Kurokawa, University of Tokyo Department of Hematology and Oncology, Graduate Schoo...
Source: Annals of Hematology - November 10, 2009 Category: Hematology Tags: Annals of Hematology Source Type: journals

Voreloxin Granted Orphan Drug Status for Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The US Food and Drug Administration has granted orphan drug designation for voreloxin in the treatment of acute myeloid leukemia. Medscape Medical News (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 10, 2009 Category: Consumer Health News Tags: Pharmacist Source Type: news

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 10, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

EpiCept Corporation Announces Health Canada Accepts Ceplene(R) Application For ReviewEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
EpiCept Corporation (Nasdaq and OMX Nordic Exchange: EPCT) today announced that Health Canada has accepted for review the Company's New Drug Submission (NDS) for Ceplene® (histamine dihydrochloride) for the remission maintenance of acute myeloid leukemia (AML) patients in first complete remission. Health Canada's performance target for the completion of review and a decision is within 300 days. (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 10, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective of this study was to determine the prevalence of neuropathy and its impact on motor function and quality of life (QOL) among children who survived ALL. Thirty-seven survivors of childhood ALL aged 8[ndash]18 underwent evaluation for neuropathy through self-reported symptoms, standardized examinations, and nerve conduction studies (NCS). Functional impact of neuropathy was assessed using the Bruininks-Oseretsky test of Motor Proficiency (BOT-2). QOL was assessed using the PedsQL. Nerve conduction study abnormalities were seen in 29.7% of children who were longer than 2 years off therapy for ALL. Most children ...
Source: Journal of the Peripheral Nervous System - November 10, 2009 Category: Neurology Authors: Sindhu Ramchandren, Marcia Leonard, Rajen J. Mody, Janet E. Donohue, Judith Moyer, Raymond Hutchinson, James G. Gurney Tags: RESEARCH REPORTS Source Type: journals

CLIP down-modulation enhances the immunogenicity of myeloid leukemic blasts resulting in increased CD4+ T cell responses.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions These data emphasize the relevance of CLIP expression on leukemic blasts and the potential of CLIP as a target for immunomodulatory strategies to enhance HLA class II antigen presentation and CD4(+) T cell reactivity in AML. PMID: 19903675 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - November 10, 2009 Category: Hematology Authors: van Luijn MM, Chamuleau ME, Thompson JA, Ostrand-Rosenberg S, Westers TM, Souwer Y, Ossenkoppele GJ, van Ham SM, van de Loosdrecht AA Tags: Haematologica Source Type: journals

Additional chromosome abnormalities in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions However, neither ACA overall nor any specific abnormality were identified as independent risk factor for relapse in multivariate analysis. The lack of independent prognostic value of ACA in APL does not support the use of alternative therapeutic strategies based on this cytogenetic finding. PMID: 19903674 [PubMed - as supplied by publisher] (Source: Haematologica)
Source: Haematologica - November 10, 2009 Category: Hematology Authors: Cervera J, Montesinos P, Hernández-Rivas JM, Calasanz MJ, Aventín A, Ferro MT, Luño E, Sánchez J, Vellenga E, Rayón C, Milone G, de la Serna J, Rivas C, González JD, Tormo M, Amutio E, González M, Brunet S, Lowenberg B, Tags: Haematologica Source Type: journals

Evaluation of in vivo antineoplastic effects of rapamycin in patients with chemotherapy-refractory AML.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSION: Rapamycin at 2mg per day acts mildly cytoreductive in a subgroup of patients with refractory AML. Higher doses and drug combinations may be required to obtain long lasting anti-leukemic effects in these patients. PMID: 19892307 [PubMed - in process] (Source: European Journal of Internal Medicine)
Source: European Journal of Internal Medicine - November 8, 2009 Category: Internal Medicine Authors: Boehm A, Mayerhofer M, Herndlhofer S, Knoebl P, Sillaber C, Sperr WR, Jaeger U, Valent P Tags: Eur J Intern Med Source Type: journals

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients With BCR-ABL T315I MutationEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In patients with BCR-ABL–positive (Ph+) leukemia, the T315I mutation is associated with a high degree of resistance to imatinib, dasatinib, and nilotinib. Little published information exits regarding the... The... (Source: OncologySTAT Journal Scans)
Source: OncologySTAT Journal Scans - November 7, 2009 Category: Cancer & Oncology Source Type: journals

ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic LeukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 7, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

ERYtech Pharma Starts Its Pivotal Clinical Trial For GRASPA(R) In Acute Lymphoblastic LeukaemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
ERYtech Pharma announces the start of its pivotal clinical trial for GRASPA®, its lead product in Acute Lymphoblastic Leukaemia. This phase III trial has begun in France and will be enlarged to a European scale. Up to 80 patients with relapsed Acute Lymphoblastic Leukaemia, aged from 1 to 55 years old will be enrolled. The endpoint combines safety and efficacy with regard to the asparagine depletion level. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - November 7, 2009 Category: Cancer & Oncology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Daunorubicin Versus Mitoxantrone Versus Idarubicin As Induction and Consolidation Chemotherapy for Adults With Acute Myeloid Leukemia: The EORTC and GIMEMA Groups Study AML-10 [Hematologic Malignancies]Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusion In adult patients with AML who do not receive an allogeneic SCT, the use of mitoxantrone or idarubicin instead of daunorubicin enhances the long-term efficacy of chemotherapy. (Source: Journal of Clinical Oncology)
Source: Journal of Clinical Oncology - November 6, 2009 Category: Cancer & Oncology Authors: Mandelli, Vignetti, Suciu, Stasi, Petti, Meloni, Muus, Marmont, Marie, Labar, Thomas, Di Raimondo, Willemze, Liso, Ferrara, Baila, Fazi, Zittoun, Amadori, de Witte Tags: Clinical Trials, leukemia, Chemotherapy Hematologic Malignancies Source Type: journals

Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is requiredEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The objective in this paper is to compare the cumulative incidence and incidence density of therapy-related acute myeloid leukaemia in two cohorts of patients with multiple sclerosis treated with mitoxantrone, and with previously reported data in the literature. Six new cases of acute myeloid leukaemia were observed by prospectively following two Spanish series of 142 and 88 patients with worsening relapsing multiple sclerosis and secondary-progressive disease treated with mitoxantrone. A literature review shows 32 further cases of acute myeloid leukaemia reported, 65.6% of which are therapy-related acute promyelocytic leu...
Source: Multiple Sclerosis - November 6, 2009 Category: Neurology Authors: Pascual, A. M, Tellez, N., Bosca, I., Mallada, J., Belenguer, A., Abellan, I., Sempere, A. P, Fernandez, P., Magraner, M. J., Coret, F., Sanz, M. A, Montalban, X., Casanova, B. Tags: Articles Source Type: journals

Targeted Delivery of Antisense Oligodeoxynucleotide by Transferrin Conjugated pH-Sensitive Lipopolyplex Nanoparticles: A Novel Oligonucleotide-Based Therapeutic Strategy in Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Molecular Pharmaceutics, Volume 0, Issue 0, Articles ASAP (As Soon As Publishable). (Source: Molecular Pharmaceutics)
Source: Molecular Pharmaceutics - November 6, 2009 Category: Drugs & Pharmacology Tags: article Source Type: journals

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - November 6, 2009 Category: Consumer Health News Tags: Lymphoma / leukemia / Myeloma Source Type: news

Sunesis' Voreloxin Receives FDA Orphan Drug Designation For Acute Myeloid LeukemiaEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS) announced that the U.S. Food and Drug Administration has granted voreloxin orphan drug designation for the treatment of acute myeloid leukemia (AML). (Source: Lymphoma / Leukemia News From Medical News Today)
Source: Lymphoma / Leukemia News From Medical News Today - November 6, 2009 Category: Hematology Tags: Lymphoma / leukemia / Myeloma Source Type: news

Antigen receptor gene rearrangements reflect on the heterogeneity of adult Acute Lymphoblastic Leukaemia (ALL) with implications of cell-origin of ALL subgroups – a UKALLXII studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Cytogenetic and molecular investigations of Acute Lymphoblastic Leukaemia (ALL) have identified the existence of distinct clinical subgroups. Molecular monitoring of clonal Immunoglobulin and T cell receptor (IG/TR) gene rearrangements has become an important tool in stratification of therapy of ALL. In order to determine whether certain features of the patient-specific rearrangements could hold further prognostic clues or provide information on the cell of origin of ALL, a comprehensive analysis of structural and biological features (V gene usage, coding frame and mutational status and complementarity-determining region -...
Source: British Journal of Haematology - November 6, 2009 Category: Hematology Authors: Lena Rai, Anouska Casanova, Anthony V. Moorman, Sue Richards, Georgina Buck, Anthony H. Goldstone, Adele K. Fielding, Letizia Foroni Source Type: journals

Invasive aspergillosis in patients with acute myeloid leukemia: SEIFEM-2008 registry studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Pagano L, Caira M, Candoni A, Offidani M, Martino B, Specchia G, Pastore D, Stanzani M, Cattaneo C, Fanci R, Caramatti C, Rossini F, Luppi M, Potenza L, Ferrara F, Mitra ME, Fadda RM, Invernizzi R, Aloisi T, Picardi M, Bonini A, Vacca A, Chierichini A, Melillo L, de Waure C, Fianchi L, Riva M, Leone G, Aversa F, Nosari A. (Source: The Aspergillus Website - articles)
Source: The Aspergillus Website - articles - November 6, 2009 Category: Respiratory Medicine Source Type: consumer